Clinical Trial: Therapy for Advanced NSCLC With EGFR 19delins Mutation

U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07458919) titled 'Therapy for Advanced NSCLC With EGFR 19delins Mutation' on March 01.

Brief Summary: In a retrospective analysis of 3,054 advanced NSCLC patients, 41 with EGFR exon 19 deletion-insertions (19delins) received first-generation EGFR TKIs, achieving median PFS of 10.4 months; those with L747\_T751delinsP had notably longer PFS of 18.7 months. Another study of 2,467 treatment-naive patients found 93 with 19delins treated with first-generation TKIs had median PFS of 19 months, exceeding the 13 months for common 19del mutations. For third-generation TKIs, a study of 215 19delins patients (57 first-line) showed median PFS of 12.9 months, in...